

R098-13

NAC 639.010, NAC 639.250, NAC 639.391, NAC 639.392, NAC 639.393, NAC 639.395, NAC 639.396, NAC 639.397, NAC 639.398, NAC 639.399, NAC 639.742, NAC 639.744, NAC 639.752, NAC 639.918, NAC 639.924, NAC 639.945, NAC 639.394.

Telepharmacies, Remote Sites and Satellite Consultation Sites

February 14, 2014

### INFORMATIONAL STATEMENT

The informational statement required by NRS 233B.066 numerically conforms to the subsections of the statute as follows:

1. EXPLANATION OF THE NEED FOR THE ADOPTED REGULATION

The proposed change amends a number of regulations in NAC Chapter 639 concerning telepharmacies, remote sites and satellite consultation sites; revising regulatory provisions governing unprofessional conduct by the holder of a license, certificate or registration issued by the Board of Pharmacy; and provides for other related matters. The proposed amendments are intended to bring the provisions of NAC Chapter 639 in line with the provisions of SB 327.

2. A DESCRIPTION OF HOW PUBLIC COMMENT WAS SOLICITED, A SUMMARY OF PUBLIC RESPONSE, AND AN EXPLANATION HOW OTHER INTERESTED PERSONS MAY OBTAIN A COPY OF THE SUMMARY.

The Board solicited comment on the proposed amendment by (1) posting a summary of the proposed amendment on the Board's website ([bop.nv.gov](http://bop.nv.gov)) with a link to the full text of the proposed amendment, (2) soliciting comment from Nevada dispensers who receive Board of Pharmacy notifications using a facsimile notice directed to each, and (3) contacting a representative of each relevant industry association Board Staff deemed likely to have an interest in the proposed amendment. The Board also provided time for public comment at the workshop(s) concerning the proposed amendment, and opened the floor for public comment at the public hearing on the proposed amendment.

Board Staff received positive comments on R098-13 from the Nevada Board of Medical Examiners, the Retail Association of Nevada and a representative from the hospital industry, although no one testified at the hearing.

Parties interested in obtaining a copy of the summary of the proposed amendment, or that wish to view the text of the proposed amendment, may access that information on the Board's website at [bop.nv.gov](http://bop.nv.gov), or by contacting the Board's office at (775) 850-1440.

3. THE NUMBER OF PERSONS WHO: (A) ATTENDED EACH HEARING; (B) TESTIFIED AT EACH HEARING; AND (C) SUBMITTED TO THE AGENCY WRITTEN STATEMENTS.

The number of persons who attended the hearing was 20.

The number of persons who testified at the hearing was -0-.

The number of agency submitted statements was -0-.

The name of persons who testified at the hearing:

4. A DESCRIPTION OF HOW COMMENT WAS SOLICITED FROM AFFECTED BUSINESSES, A SUMMARY OF THEIR RESPONSE, AND AN EXPLANATION HOW OTHER INTERESTED PERSONS MAY OBTAIN A COPY OF THE SUMMARY.

Comments were solicited from affected businesses through posting of public notices in the county courthouses, by direct mailings to all interested persons who have requested notices of board of pharmacy meeting agendas, by direct mailings to professional and trade associations, posting a summary of the proposed amendment on the Board's website ([bop.nv.gov](http://bop.nv.gov)), with a link to the full text of the proposed amendment, and soliciting comment from Nevada pharmacies who receive Board of Pharmacy "Hotline" notifications using a facsimile notice directed to each.

There was no response from affected businesses relative to this proposed regulation.

Parties interested in obtaining a copy of the summary of the proposed amendment, or that wish to view the text of the proposed amendment, may access that information on the Board's website at [bop.nv.gov](http://bop.nv.gov), or by contacting the Board's office at (775) 850-1440.

5. IF THE REGULATION WAS ADOPTED WITHOUT CHANGING ANY PART OF THE PROPOSED REGULATION, A SUMMARY OF THE REASONS FOR ADOPTING THE REGULATION WITHOUT CHANGE.

The proposed regulation was adopted without changes because the Board members found them appropriate to comply with SB 327, and because the Board received no comment in support of or in opposition to the proposed regulation.

6. THE ESTIMATED ECONOMIC EFFECT OF THE REGULATION ON THE BUSINESS WHICH IT IS TO REGULATE AND ON THE PUBLIC. THESE MUST BE STATED SEPARATELY, AND IN EACH CASE MUST INCLUDE:

A) BOTH ADVERSE AND BENEFICIAL EFFECTS.

This regulation should have no adverse or beneficial economic effect on pharmacies, the small businesses it is most likely to impact, or on the public.

B) BOTH IMMEDIATE AND LONG-TERM EFFECTS.

The Board anticipates that this regulation will have no immediate or long-term economic effects on pharmacies or the public.

7. THE ESTIMATED COST TO THE AGENCY FOR ENFORCEMENT OF THE PROPOSED REGULATION.

There will be no additional or special costs incurred by the board for enforcement of this regulation.

8. A DESCRIPTION OF ANY REGULATIONS OF OTHER STATE OR GOVERNMENT AGENCIES WHICH THE PROPOSED REGULATION OVERLAPS OR DUPLICATES AND A STATEMENT EXPLAINING WHY THE DUPLICATION OR OVERLAPPING IS NECESSARY. IF THE REGULATION OVERLAPS OR DUPLICATES A FEDERAL REGULATION, THE NAME OF THE REGULATING FEDERAL AGENCY.

The Board is not aware of any similar regulations of other state or government agencies that the proposed regulation overlaps or duplicates.

9. IF THE REGULATION INCLUDES PROVISIONS WHICH ARE MORE STRINGENT THAN A FEDERAL REGULATION WHICH REGULATES THE SAME ACTIVITY, A SUMMARY OF SUCH PROVISIONS.

The Board is not aware of any similar regulations of the same activity in which the federal regulation is more stringent.

10. IF THE REGULATION PROVIDES A NEW FEE OR INCREASES AN EXISTING FEE, THE TOTAL ANNUAL AMOUNT THE AGENCY EXPECTS TO COLLECT AND THE MANNER IN WHICH THE MONEY WILL BE USED.

This regulation does not provide a new or increase of fees.